The value of early detection is perhaps greater for cancer than many other diseases because it remains the second leading cause of death worldwide. On this episode of Raise the Line we're going to learn about a new testing approach that leverages genomic technology and machine learning to detect signals circulating in the blood across more than 50 types of cancers -- far beyond the number currently screened for -- and helps physicians target locations for diagnostic evaluation. “We can look at this epigenetic pattern on very specific regions of the DNA and say this is only seen in cancer, and make a call,” says Dr. Josh Ofman, the president of GRAIL, a spinoff of the genomic sequencing company Illumina. “We have an opportunity now to dramatically improve the number of cancers found in the population through early detection. We could reduce the death rate over the next five years by almost forty percent,” he tells host Shiv Gaglani. Tune in to find out who qualifies for the test, what obstacles lie ahead and how GRAIL is working to educate physicians about this potentially powerful new option Mentioned in this episode: https://grail.com/